Variety of qualified sufferers: CDEC discussed the uncertainty in the number of sufferers with moderately significant to extreme hemophilia B in Canada suitable for etranacogene dezaparvovec. Medical industry experts consulted by CADTH indicated that some clients that are categorised as obtaining ge